Amyloidosis: Risk Factors, Treatment Options and Clinical Aspects

$95.00

Raquel Watts (Editor)

Series: New Developments in Medical Research
BISAC: MED000000

Amyloidosis is a result of the abnormal deposition of ‘amyloid’ resulting in the disruption of organ and tissue function, which can be localized or systemic, with the kidney being most frequently affected. This book discusses the risk factors, treatment options and clinical aspects of amyloidosis. Chapter One explores amyloid cardiomyopathy. Chapter Two summarizes current investigations utilizing RNAi and immunotherapy to target the amyloid protein itself. Chapter Three reviews genetic counseling as an important component of the treatment algorithm for amyloidosis. Chapter Four discusses tissue examination in a diagnostic procedure. Chapter Five reviews protein studies in light-chain amyloidosis. (Imprint: Nova Biomedical)

Clear

Details

Table of Contents

Preface

Chapter 1. Amyloid Cardiomyopathy
Tomas Pika and Jiri Vymetal (Department of Hemato-oncology, University Hospital Olomouc, Czech Republic, and others)

Chapter 2. Novel Therapies for Amyloidosis in the Era of RNAi and Immunotherapy
Sandy W. Wong and Raymond L. Comenzo (Departments of Medicine and Pathology and the Division of Hematology-Oncology,
Tufts Medical Center, Boston, MA, USA)

Chapter 3. Clinical Management of Amyloidosis: Genetic Counseling as an Important Component of the Treatment Algorithm
Jennifer Davey, Jen Bevilacqua, Andrew Hesse, and Honey V. Reddi (Transgenomic Inc, New Haven, CT, USA, and others)

Chapter 4. Tissue Examination in a Diagnostic Procedure
Flodrova Pavla, Pika Tomas and Flodr Patrik (Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic, and others)

Chapter 5. Protein Studies in Light-Chain Amyloidosis
Pavel Lochman (Faculty Hospital Olomouc, Department of Clinical Chemistry, Olomouc, Czech Republic)

Bibliography

Related Nova Publications

Index

Additional information

Binding

,